Mind Medicine (MindMed) Inc N.MMED.WR

Primary Symbol: MNMD Alternate Symbol(s): N.MMED.WS | N.MMED.WA | N.MMED

Healthcare

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).

NDAQ:MNMD - Post by User

Mind Medicine (MindMed) Inc > Too much hype over the new listing.

<< Previous

Bullboard Posts

Next >>

Comment by trader53on Apr 27, 2021 3:56pm

345 Views

Post# 33076217

RE:RE:Too much hype over the new listing.

Not at all far too much hype and the market cap is beyond crazy. Looks like the first dollar has evaporated and I fully expect that the other dollar of smoke will also evaporate before weeks end. A sharp pullback in the SPY would absolutely destroy MMED along with many more Companies that have 0 revenues. Keep an eye on the insider selling as the last time this stock saw this price level the insiders were shovelling their options and warrants out the door.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario